Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association（2018）
摘要
In the Korean EAP cohort, ramucirumab showed similar efficacy to the results of the previous trials for gastric cancer. However, the level of GI perforation was slightly increased in the ramucirumab plus paclitaxel group.
更多查看译文
关键词
Expanded access program,Gastric cancer,Ramucirumab,Second-line chemotherapy,Vascular endothelial growth factor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要